Introduction
============

Head and neck carcinoma represents one of the 10 most common cancers worldwide.[@b1-ott-10-1527] More than 95% of head and neck cancers are squamous cell carcinoma (head and neck squamous cell carcinoma \[HNSCC\]), indicating that it is relatively a homogeneous disease. However, the wide spectrum of unexpected genetic aberrations that have been observed in recent genomic studies[@b2-ott-10-1527],[@b3-ott-10-1527] highlighted the molecular heterogeneity of the disease. Despite aggressive and diverse therapies, the survival rate of these patients has not markedly improved because of the frequent development of locoregional recurrences, distant metastases, and second primary tumors.[@b4-ott-10-1527]

Epidermal growth factor receptor (EGFR) protein overexpression is seen in \>80% of HNSCC cases[@b5-ott-10-1527] and is associated with a poor prognosis.[@b6-ott-10-1527] The overexpression of EGFR may apparently be triggered by numerous mechanisms such as epigenetic changes, gene amplification, and oncogenic viruses.[@b7-ott-10-1527] Hypoxic tumor microenvironment increases the EGFR mRNA translation, thereby inducing EGFR overexpression.[@b8-ott-10-1527] EGFR is a founding member of a HER (erbB) family, which consists of four closely related transmembrane receptors.[@b9-ott-10-1527] EGFR has a single hydrophobic transmembrane domain, a cytoplasmic tyrosine kinase (TK)-containing domain, and an extracellular ligand-binding domain.[@b10-ott-10-1527] The cascade on binding of a ligand to the latter domain initiates the EGFR oligomerization followed by autophosphorylation based on the activation of TK residue at C terminus. The phosphorylated tyrosine becomes a binding site for SH2 (Src homology 2) or PTB (phosphotyrosine Binding) domain-containing signaling molecules, including growth factor receptor-bound protein (GRB2) and phosphatidylinositol-3,4,5-triphosphate (PIP3). This initiates a cascade of downstream intracellular signal transduction pathways, namely, mitogen-activated protein kinase (MAPK), phosphatidylinositol-3-kinase (PIK3)-AKT, and signal transducer and activator of transcription (STAT),[@b11-ott-10-1527] which regulate cell proliferation, differentiation, invasion, angiogenesis, and metastasis.[@b12-ott-10-1527] The *EGFR* gene is frequently overexpressed and mutated in human cancers, which is one of the driving forces behind the development of drugs to target the EGFR in general and TK in particular.

The TK domain mutations mostly occur between exons 18 and 21, which constitute single-base substitutions, insertions, and deletions. Alterations in exons 19 and 21 are most common in non-small cell lung carcinoma (NSCLC), which is the reason that this carcinoma responds to EGFR-tyrosine kinase inhibitors (TKIs).[@b13-ott-10-1527],[@b14-ott-10-1527] However, theoretically, most of the mutations in the TK domain result in conformational change, which regulates the sensitivity of TKI therapy.[@b15-ott-10-1527]

These hot spot mutations (exons 18--21) of the *EGFR* gene were mostly studied in NSCLC, and the mutation frequency was ethnically specific.[@b16-ott-10-1527] Sparse data are available on EGFR-TK domain mutations in HNSCC globally and in the Saudi population. Previously, the *PIK3CA* mutation pattern in HNSCC patients of Saudi origin was studied, and a high frequency of *PIK3CA* mutations and five novel mutations were reported.[@b17-ott-10-1527] The PI3K signaling molecules upon binding to the phosphorylated TK initiate a cascade of intracellular signal transduction pathways.

Therefore, the study of the prevalence of mutations in EGFR-TK in our population may be used as a predictive biomarker resulting in the provision of personalized treatment and shed some light on furthering the understanding of the genetic nature of the EGFR-TK domain. Molecular profiling of tumors, with a particular focus on genetic alterations, is essential to reduce the disease burden and increase the survival rate through improved therapies and more accurate prognosis. To explore the aforementioned hypothesis, the spectrum of mutations in exons 18--21 of the *EGFR* gene was investigated in 47 HNSCC cases.

Materials and methods
=====================

Tissue samples
--------------

This retrospective study was conducted on a total of 47 formalin-fixed paraffin-embedded tissue samples from HNSCC tumors from Saudi patients with HNSCC who attended from the King Fahd Hospital of the university. Of the 47 samples, 20 tumors were in the nasopharynx, 13 in the larynx, 4 in the hypopharynx, and 5 each in the oropharynx and the oral cavity. None of the patients underwent any pre-surgical intervention, including radiotherapy and/or chemotherapy. This study was approved by the Institutional Review Board of University of Dammam (\#IRB-2014-08-044). All the participants in the research study gave written informed consent. Demographical and clinical parameter details were collected from the hospital records.

Microdissection
---------------

Each tumor tissue block with \>70% tumor content was cut into four 10 µm sections using a microtome (SLEE Medical, Mainz, Germany).

Genomic DNA isolation
---------------------

Genomic DNA was isolated by using QIAamp DNA FFPE tissue kit (Qiagen, Manchester, UK) as per the manufacturer's instructions.

Quantification of DNA
---------------------

The concentration of the extracted DNA was determined by using Nanodrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). The average DNA quantity observed was 95.1 ng/µL and the purity was 2.1.

Control assay
-------------

As per the Therascreen^®^ EGFR-Rotor-Gene Q (RGQ) polymerase chain reaction (PCR) kit (Qiagen, Hilden, Germany) mandate, the total amplifiable DNA for each sample was assessed on RGQ real-time PCR (Qiagen) using the control reaction mix. Control assay amplifies the exon 2 region of the *EGFR* gene. All the samples fulfilled the criteria of C~T~ value between 23 and 30.69 in the green channel.

Mutation assay
--------------

The Therascreen EGFR RGQ PCR kit (Qiagen) detects a total of 29 ([Figure 1](#f1-ott-10-1527){ref-type="fig"}) specific somatic mutations in exons 18--21 of the *EGFR* gene utilizing both ARMS^®^ and Scorpion^®^ technologies. Data analysis was performed by using Rotor gene proprietary software, and the mutation status was categorized qualitatively as positive and negative based on the Therascreen EGFR RGQ PCR kit guidelines.

Statistical analysis
--------------------

The results were categorized as positive or negative for each mutation of the *EGFR* gene, and the Fisher exact test was used to test the proportions across the cohort with variables such as age, gender, smoking status, tumor grade, stage, and prognosis was analyzed by using Statistical Package for the Social Sciences (SPSS) version 18 software (SPSS Inc., Chicago, IL, USA).

Results
=======

The patient cohort comprised Saudi nationals with a median age of 52 years. The gender ratio skewed toward males (66%). The majority of tumors were nasopharyngeal squamous cell carcinoma tumors (42.5%), followed by laryngeal tumors (27.6%), with the remainder mainly comprising hypopharyngeal, oropharyngeal, and oral cavity. Stage 1 and 2 HNSCC represented 40.5% of the cancers, whereas stages 3 and 4 represented 59.5%. In the cohort, both grade 3 and grade 2 tumors were represented equally (40.5% each), followed by grade 1 tumors (19%). Data reflected that 44.7% of patients whose tumor samples were included in the study were smokers ([Table 1](#t1-ott-10-1527){ref-type="table"}).

Twenty-seven patients (57%) exhibited at least one of the specific somatic mutation in the EGFR-TK domain spanning exons 18--21. Of the total mutations, L861Q (exon 21), exon 20 insertions, and deletions of exon 19 accounted for the majority of the mutations (21%, 19%, and 17%, respectively). The resistant mutation T790M (exon 20) and G719A/S/C (exon 18) were the least observed (8.5%). Grade 3 tumors had a statistically significant higher rate of mutations compared with low-grade tumors (*P*=0.041) ([Table 2](#t2-ott-10-1527){ref-type="table"}). Similarly, advanced stage tumors were correlated with a high rate of mutation status (*P*=0.034). Smoking status, gender, and age did not yield any significant correlation with the mutation status.

Furthermore, each specific mutation was compared with specific categories, namely, gender, age (\<50 and \>50 years), smoking status, and prognosis ([Table 3](#t3-ott-10-1527){ref-type="table"}). The male population had a significantly higher mutation rate of exon 20 insertions (*P*=0.019). Patients aged \<50 years had more exon 19 deletions compared with those aged \>50 years (*P*=0.047).

Discussion
==========

The overexpression of EGFR is observed in several malignancies, such as NSCLC, renal cancer, colon cancer, breast cancer, ovarian cancer, and HNSCC. The overexpression of this protein is correlated with a decreased occurrence of disease-free survival.[@b18-ott-10-1527]--[@b23-ott-10-1527] Monoclonal antibodies block the ligand-binding region of EGFR and reduce the TK activation.[@b24-ott-10-1527],[@b25-ott-10-1527] Currently, the FDA-approved anti-EGFR monoclonal antibodies are cetuximab and panitumumab, with the former for HNSCC and both for colorectal cancer.[@b16-ott-10-1527] Small molecule TKIs bind to the intracellular catalytic domain of the EGFR and inhibit their autophosphorylation and downstream signaling.[@b26-ott-10-1527]

Preliminary studies on TKIs such as gefitinib and erlotinib established biological and clinical activity in limited phenotypic and genotypic subclass of lung cancers.[@b27-ott-10-1527] Further exploration revealed optimum response observed in patients who have TK domain mutations. Those mutations are exon 18 (G719X), exon 19 deletions, and exon 21 (L858R) mutations.[@b28-ott-10-1527] The acquired resistance was observed in patients having T790M mutation at exon 20.[@b29-ott-10-1527] Recent studies and clinical trials in NSCLC indicate that patients having *EGFR* mutations show a promising response to the TKIs. Therefore, the study of *EGFR* mutations in various cancers has gained a lot of importance.

In HNSCC, *EGFR* mutation frequency differed in ethnic populations, ranging from 7% in Japanese population,[@b30-ott-10-1527] 7.3% in Asian population,[@b31-ott-10-1527] 15.7% in Korean population,[@b32-ott-10-1527] and 15.8% in Greek population.[@b33-ott-10-1527] The highest mutation frequency was 81.39% in southern Indian population.[@b34-ott-10-1527] No mutations were observed in Belgium[@b16-ott-10-1527] and Spanish[@b35-ott-10-1527] populations. Novel mutations were identified in Japanese and southern Indian populations.[@b30-ott-10-1527],[@b34-ott-10-1527] The present study observed a frequency of 57% *EGFR* mutation among the Saudi population. This EGFR polymorphic variation in HNSCC is ethnically specific, with varying prevalence in different populations.[@b36-ott-10-1527] The variation may also be due to the method of *EGFR* mutation detection used, which may include Sanger sequencing, hybridization, immunohistochemistry, and real-time PCR. Each assay varies in its sensitivity and specificity. The present study used the Therascreen EGFR RGQ PCR kit for the detection of specific somatic mutations in the *EGFR* oncogene. This method detects mutation as low as 0.5% in the background of wild-type DNA.

The major etiological factors for HNSCC are smoking and alcohol consumption, which is why men are at a higher risk than females.[@b30-ott-10-1527] Our study cohort is in line with this, as 66% of the patients were males and 58% of the male patient group were smokers compared with 18.75% in female patients. It is known that the higher-grade HNSCC tumors are associated with a higher number of mutations.[@b17-ott-10-1527] This has also been confirmed by the present study, where a higher number of mutations were observed in high pathological grade tumors (*P*=0.026).

Molecular studies on HNSCC cohorts revealed that 6.9%[@b37-ott-10-1527] and 10.5%[@b30-ott-10-1527] of the patients had a deletion in exon 19 and that the former cohort exhibited a poor prognosis when treated with cetuximab and radiotherapy. Hama et al reported that patients with exon 19 deletions and exon 21 point mutations who had been treated with gefitinib had longer progression and survival times (7.7 vs 2.2 months and 11.6 vs 4.6 months, respectively) when compared with patients who had wild-type *EGFR* mutation. In the present study, 17% of patients exhibited a deletion in exon 19, and it was observed that this mutation had a higher prevalence in younger patients (*P*=0.047) and also that exon 20 insertions in 19% of the study cohort and all the insertions in exon 20 were only observed in male patients (*P*=0.019).

The frequency of exon 18 mutation in our population was 8.5% compared with that found in Indian population (58%).[@b34-ott-10-1527] The T790M mutation in exon 20, which is resistant to TKI therapy, was observed in four patients in the present cohort. The present study seems to be the first study reporting the T790M mutation in a HNSCC cohort. Based on the above data, the high frequency of exon 19 deletions and low frequency of T790M resistant mutation indicate that TKIs may be used as an effective treatment strategy. The coexistence of several mutations in the *EGFR* gene may shed some light on the HNSCC prognosis.

Conclusion
==========

The higher frequency of EGFR-TK domain mutations together with the presence of the T790M mutation suggests that identification of these mutations might streamline the therapy and provide a better prognosis in HNSCC cases.
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###### 

Patient characteristics

  S No                    Parameter            Number (%)
  ----------------------- -------------------- ------------
  1                       Gender               
   Male                   31 (66)              
   Female                 16 (34)              
  2                       Median age (years)   52
  3                       Grade                
   Grade 1                9 (19)               
   Grade 2                19 (40.5)            
   Grade 3                19 (40.5)            
  4                       Stage                
   Stage 1 and 2 tumors   19 (40.5)            
   Stage 3 and 4 tumors   28 (59.5)            
  5                       Smoking status       
   Smokers                21 (44.7)            
   Nonsmokers             26 (55.3)            
  6                       Ethnicity            Saudi

###### 

Effect of parameters on EGFR mutation

  Parameter        Mutation (n)   No mutation (n)   *P*-value
  ---------------- -------------- ----------------- -----------
  Grade 1          2              7                 
  Grade 2          12             7                 0.103
  Grade 3          13             6                 0.041
  Grade 2 and 3    25             13                0.026
  Stage 1 and 2    7              12                
  Stage 3 and 4    20             8                 0.034
  Male             20             11                
  Female           7              9                 0.22
  Smoker           14             7                 
  Nonsmoker        13             13                0.374
  Good prognosis   7              8                 
  Bad prognosis    20             12                0.355
  ≥50 years        15             13                
  \<50 years       12             7                 0.561

**Abbreviation:** EGFR, epidermal growth factor receptor.

###### 

Association of age, gender, smoking status, and prognosis with the individual EGFR mutations

  Exon                            Gender      Age     Smoking status   Prognosis   Mutation frequency                                                                   
  ------------------ ------------ ----------- ------- ---------------- ----------- -------------------- ----------- ----------- ------- ----------- ----------- ------- -----------
  18                 G719A/S/C                                                                                                                                          
   Mutation          3 (75)       1 (25)      1       2 (50)           2 (50)      1                    3 (75)      1 (25)      0.311   2 (50)      2 (50)      0.582   4 (8.5)
   No mutation       28 (65.1)    15 (34.9)           17 (39.5)        26 (60.5)                        18 (41.9)   25 (58.1)           13 (30.2)   30 (69.8)           
  19                 Deletions                                                                                                                                          
   Mutation          4 (50)       4 (50)      0.416   6 (75)           2 (25)      0.047                3 (37.5)    5 (62.5)    0.715   2 (25)      6 (75)      1       8 (17)
   No mutation       27 (69.2)    12 (30.8)           13 (33.3)        26 (66.7)                        18 (46.2)   21 (53.8)           13 (33.3)   26 (66.7)           
  20                 Insertions                                                                                                                                         
   Mutation          9 (100)      0 (0)       0.019   1 (11)           8 (99)      0.064                6 (66.7)    3 (33.3)    0.263   1 (11)      8 (99)      0.236   9 (19)
   No mutation       22 (58)      16 (42)             18 (47.4)        20 (52.6)                        15 (39.5)   23 (60.5)           14 (36.8)   24 (63.2)           
  20                 S768I                                                                                                                                              
   Mutation          5 (83.3)     1 (16.7)    1       5 (83.3)         1 (16.7)    0.101                4 (66.6)    2 (33.4)    0.683   2 (33.4)    4 (66.6)    1       6 (13)
   No mutation       26 (63.4)    15 (36.6)           14 (34.1)        27 (65.9)                        17 (41.5)   24 (58.5)           13 (31.7)   28 (68.3)           
  20                 T790M                                                                                                                                              
   Mutation          3 (75)       1 (25)      1       1 (25)           3 (75)      0.637                2 (50)      2 (50)      1       0 (0)       4 (100)     0.29    4 (8.5)
   No mutation       28 (65.1)    15 (34.9)           18 (41.9)        25 (58.1)                        19 (44.2)   24 (55.8)           15 (34.9)   28 (65.1)           
  21                 L858R                                                                                                                                              
   Mutation          4 (66.7)     2 (33.3)    1       2 (33.3)         4 (66.7)    1                    4 (66.7)    2 (33.3)    0.385   2 (33.3)    4 (66.7)    1       6 (13)
   No mutation       27 (65.9)    14 (34.1)           17 (41.5)        24 (58.5)                        17 (41.5)   24 (58.5)           13 (31.7)   28 (68.3)           
  21                 L861Q                                                                                                                                              
   Mutation          7 (70)       3 (30)      1       5 (50)           5 (50)      0.496                3 (30)      7 (70)      0.475   2 (20)      8 (80)      0.465   10 (21)
   No mutation       24 (64.9)    13 (35.1)           14 (37.8)        23 (62.2)                        18 (48.6)   19 (51.4)           13 (48.1)   24 (64.9)           
  Overall mutation                                                                                                                                                      
   Mutation          20 (74)      7 (26)      0.22    12 (44.4)        15 (55.6)   0.561                14 (51.9)   13 (48.1)   0.374   7 (26)      20 (74)     0.355   27 (57.4)
   No mutation       11 (55)      9 (45)              7 (35)           13 (65)                          7 (35)      13 (65)             8 (40)      12 (60)             

**Abbreviation:** EGFR, epidermal growth factor receptor.
